CIK 2039349
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 90.81% | 14 |
| Health Care Equipment & Supplies | 6.35% | 1 |
| Life Sciences Tools & Services | 2.84% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | KYTX | Kyverna Therapeutics, Inc. | Health Care | 25.51% |
| 2 | TSHA | Taysha Gene Therapies, Inc. | Health Care | 15.47% |
| 3 | VIR | Vir Biotechnology, Inc. | Health Care | 9.48% |
| 4 | BLCO | Bausch & Lomb Corp | Health Care | 6.35% |
| 5 | AMGN | AMGEN INC | Health Care | 4.95% |
| 6 | SRRK | Scholar Rock Holding Corp | Health Care | 4.54% |
| 7 | RARE | Ultragenyx Pharmaceutical Inc. | Health Care | 4.22% |
| 8 | PYXS | Pyxis Oncology, Inc. | Health Care | 4.19% |
| 9 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Health Care | 3.91% |
| 10 | SION | Sionna Therapeutics, Inc. | Health Care | 3.80% |
16/16 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 12% of book weight classified — the grid is NOT representative of the whole book.
Classified: 11.7% of book weight (3/16 names) · unclassified 88.3%: KYTX, TSHA, VIR, BLCO, SRRK, RARE, PYXS, SION, CLDX, INSM +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | KYTXKYVERNA THERAPEUTICS INC | 4,244,818 | $37M | 25.5% | TRIM −3% |
| 2 | TSHATAYSHA GENE THERAPIES INC | 737,550 | $22M | 15.5% | TRIM −45% |
| 3 | VIRVIR BIOTECHNOLOGY INC | 1,518,552 | $14M | 9.5% | ADD 63% |
| 4 | BLCOBAUSCH PLUS LOMB CORP | 573,472 | $9M | 6.4% | TRIM −7% |
| 5 | AMGNAMGEN INC | 20,212 | $7M | 5.0% | TRIM −13% |
| 6 | SRRKSCHOLAR ROCK HLDG CORP | 132,500 | $7M | 4.5% | NEW |
| 7 | RAREULTRAGENYX PHARMACEUTICAL IN | 289,101 | $6M | 4.2% | TRIM −12% |
| 8 | PYXSPYXIS ONCOLOGY INC | 4,121,870 | $6M | 4.2% | HOLD |
| 9 | TEVATEVA PHARMACEUTICAL INDS LTD | 1,257,495 | $6M | 3.9% | ADD 63% |
| 10 | SIONSIONNA THERAPEUTICS INC | 136,000 | $5M | 3.8% | NEW |
| 11 | CLDXCELLDEX THERAPEUTICS INC NEW | 170,307 | $5M | 3.8% | HOLD |
| 12 | INSMINSMED INC | 28,587 | $5M | 3.3% | HOLD |
| 13 | CRNXCRINETICS PHARMACEUTICALS IN | 126,985 | $5M | 3.2% | TRIM −43% |
| 14 | INCYINCYTE CORP | 43,300 | $4M | 2.8% | TRIM −21% |
| 15 | ALLOALLOGENE THERAPEUTICS INC | 1,430,000 | $3M | 2.4% | NEW |
| 16 | TARSTARSUS PHARMACEUTICALS INC | 42,680 | $3M | 2.1% | TRIM −36% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| KYTXKYVERNA THERAPEUTICS INC | — | — | — | — | 4.4M | 4.2M | $37M |
| TSHATAYSHA GENE THERAPIES INC | — | — | — | — | 1.3M | 738K | $22M |
| VIRVIR BIOTECHNOLOGY INC | — | — | — | — | 930K | 1.5M | $14M |
| BLCOBAUSCH PLUS LOMB CORP | — | — | — | — | 613K | 573K | $9M |
| AMGNAMGEN INC | — | — | — | — | 23K | 20K | $7M |
| SRRKSCHOLAR ROCK HLDG CORP | — | — | — | — | — | 133K | $7M |
| RAREULTRAGENYX PHARMACEUTICAL IN | — | — | — | — | 329K | 289K | $6M |
| PYXSPYXIS ONCOLOGY INC | — | — | — | — | 4.1M | 4.1M | $6M |
| TEVATEVA PHARMACEUTICAL INDS LTD | — | — | — | — | 770K | 1.3M | $6M |
| SIONSIONNA THERAPEUTICS INC | — | — | — | — | — | 136K | $5M |
| CLDXCELLDEX THERAPEUTICS INC NEW | — | — | — | — | 170K | 170K | $5M |
| INSMINSMED INC | — | — | — | — | 29K | 29K | $5M |
| CRNXCRINETICS PHARMACEUTICALS IN | — | — | — | — | 224K | 127K | $5M |
| INCYINCYTE CORP | — | — | — | — | 55K | 43K | $4M |
| ALLOALLOGENE THERAPEUTICS INC | — | — | — | — | — | 1.4M | $3M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
